The U.S. market was flat last week, but it is up 25% over the past 12 months and earnings are expected to grow 15% per year over the next few years. In this favorable environment, identifying high-growth technology stocks that are aligned with these trends can provide significant opportunities for investors.

The 10 fastest growing technology companies in the USA

Click here to see the full list of 250 stocks from our high-growth US tech and AI stocks screener.

Here we highlight a subset of our favorite stocks from the screener.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cellebrite DI Ltd. develops solutions for legally authorized investigations in various regions including Europe, Middle East, Africa, Americas and Asia Pacific, with a market capitalization of $3.46 billion.

Operations: Cellebrite DI Ltd. generates its revenue primarily from Internet software and services, which amounted to $346.76 million. The company focuses on developing solutions for legally sanctioned investigations in several regions worldwide.

Cellebrite DI, known for its AI-driven case-to-closure platform, reported revenue of $95.71 million for the second quarter of 2024, up 24.85% from $76.68 million last year. Despite narrowing its net loss to $23.81 million from $32.35 million, the company forecasts annual revenue growth of 14.7%, outpacing the U.S. market at 8.8%. Cellebrite’s R&D spending is substantial at about 25% of revenue, reflecting the company’s commitment to innovating in digital forensics and cybersecurity solutions for high-profile clients such as U.S. federal agencies, which generated about 19% of its annual recurring revenue from the public sector last year.

Simply Wall St Growth Rating: ★★★★★☆

Overview: SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patients with rare diseases and cancer and has a market capitalization of $2.93 billion.

Operations: SpringWorks Therapeutics focuses on developing and commercializing treatments for rare diseases and cancer. The company operates in the biopharmaceutical sector and aims to address unmet medical needs.

SpringWorks Therapeutics reported revenue of $59.73 million for the second quarter of 2024, reflecting a strong year-over-year growth trajectory. Despite a reduction in net loss from $77.93 million to $39.92 million, the company invests heavily in research and development, with expenses representing approximately 42.9% of revenue, underscoring its commitment to innovation in rare disease treatments such as mirdametinib for NF1-PN. The projected annual earnings growth rate of 71.24% and the expected revenue increase of 42.9% per year underscore its potential in the biotech sector despite recent share dilution.

Simply Wall St Growth Rating: ★★★★★☆

Overview: HubSpot, Inc., together with its subsidiaries, offers a cloud-based customer relationship management (CRM) platform for companies in North and South America, Europe, and the Asia-Pacific region with a market capitalization of $25.43 billion.

Operations: HubSpot generates its revenue primarily from its cloud-based CRM platform, with Internet Software & Services contributing $2.39 billion. The company operates in several regions, including the Americas, Europe, and Asia Pacific.

HubSpot’s revenue rose to $637.23 million in the second quarter of 2024, up significantly from $529.14 million last year, with net loss narrowing significantly from $111.8 million to $14.44 million. Reflecting its commitment to innovation, the company’s R&D spending accounted for 20% of revenue last quarter, driving the advancement of its CRM solutions and SaaS offerings. Revenue is expected to grow 14.9% annually, outperforming the U.S. market average of 8.8%, underscoring strong future prospects despite past concerns about shareholder dilution and recent M&A speculation with Alphabet Inc. that caused stock value to fluctuate.

Next Steps

• Discover the 250 names from our screener for high-growth US technology and AI stocks here.
• Do you own shares of these companies? Set up your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio’s performance.
• Harness the power of informed investing with Simply Wall St, your free guide to navigating the world’s stock markets.

Ready to venture into other investment styles?

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.

Do you have feedback on this article? Are you interested in the content? Contact us directly. Alternatively, send an email to [email protected]